SCYNEXIS transfers BREXAFEMME NDA to GSK, enabling regulatory discussions for relaunch and potential financial benefits for SCYNEXIS.
Quiver AI Summary
SCYNEXIS, Inc. has successfully transferred the New Drug Application for BREXAFEMME (ibrexafungerp) to GSK, enabling GSK to proceed with regulatory discussions with the FDA for the relaunch of BREXAFEMME, which is approved for treating vulvovaginal candidiasis (VVC) and reducing recurrent VVC incidents. Following the relaunch, SCYNEXIS could earn up to $145.5 million in annual net sales milestones along with low to mid single-digit royalties, providing a significant source of non-dilutive capital for the company. SCYNEXIS continues to innovate in antifungal treatments, with additional products under development in its fungerp platform.
Potential Positives
- SCYNEXIS has successfully completed the transfer of the BREXAFEMME NDA to GSK, enabling GSK to initiate regulatory discussions with the FDA for the product's relaunch.
- The relaunch of BREXAFEMME could provide SCYNEXIS with up to $145.5 million in annual net sales milestones, representing a significant potential revenue source.
- SCYNEXIS will also receive royalties from net sales post-relaunch, contributing to the company's non-dilutive capital flow.
- The approval of BREXAFEMME for treating vulvovaginal candidiasis and reducing recurrent cases positions SCYNEXIS favorably in the market for antifungal treatments.
Potential Negatives
- Transferring the BREXAFEMME NDA to GSK may indicate challenges SCYNEXIS faced in independently managing the product, possibly reflecting broader operational issues.
- The reliance on future net sales milestones and royalties from GSK exposes SCYNEXIS to uncertainties in revenue generation, which could affect financial stability.
- The press release emphasizes future potential rather than current achievements, suggesting that SCYNEXIS may still be in a vulnerable position regarding product performance and market acceptance.
FAQ
What is the status of BREXAFEMME?
BREXAFEMME has been successfully transferred to GSK, which is set to relaunch the product for vulvovaginal candidiasis.
How much revenue can SCYNEXIS expect from GSK?
SCYNEXIS stands to receive up to $145.5 million in annual net sales milestones and royalties from GSK.
What is the role of GSK concerning BREXAFEMME?
GSK will initiate regulatory interactions with the FDA to discuss the relaunch of BREXAFEMME.
What is ibrexafungerp?
Ibrexafungerp is the first representative of a novel class of antifungal agents developed by SCYNEXIS.
What potential risks are associated with SCYNEXIS statements?
Forward-looking statements carry risks and uncertainties, which can cause actual results to differ from projections.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SCYX Hedge Fund Activity
We have seen 17 institutional investors add shares of $SCYX stock to their portfolio, and 20 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AVIDITY PARTNERS MANAGEMENT LP added 2,121,618 shares (+172.6%) to their portfolio in Q3 2025, for an estimated $1,633,645
- FEDERATED HERMES, INC. removed 1,311,652 shares (-45.3%) from their portfolio in Q3 2025, for an estimated $1,009,972
- BRIDGEWAY CAPITAL MANAGEMENT, LLC removed 204,243 shares (-55.5%) from their portfolio in Q3 2025, for an estimated $157,267
- TABOR ASSET MANAGEMENT, LP removed 189,802 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $128,078
- VANGUARD GROUP INC added 105,600 shares (+6.4%) to their portfolio in Q3 2025, for an estimated $81,312
- CITADEL ADVISORS LLC removed 72,357 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $48,826
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 58,728 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $45,220
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$SCYX Analyst Ratings
Wall Street analysts have issued reports on $SCYX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Guggenheim issued a "Buy" rating on 10/28/2025
To track analyst ratings and price targets for $SCYX, check out Quiver Quantitative's $SCYX forecast page.
Full Release
-
GSK remains committed to the relaunch of BREXAFEMME, and following its relaunch, SCYNEXIS stands to receive up to $145.5 million in annual net sales milestones as well as royalties, net of payments to Merck, in the low to mid single digit range
JERSEY CITY, N.J., Nov. 19, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it has completed the transfer of the BREXAFEMME (ibrexafungerp) New Drug Application (NDA) to GSK.
“We are pleased to announce this important milestone for SCYNEXIS. With the transfer of the BREXAFEMME NDA now complete, GSK will be able to initiate regulatory interactions with the U.S. Food and Drug Administration (FDA) to discuss the relaunch of BREXAFEMME for vulvovaginal candidiasis (VVC) and refractory vulvovaginal candidiasis (rVVC) in the U.S. market,” said David Angulo, M.D., President and Chief Executive Officer. “Furthermore, SCYNEXIS stands to receive net sales milestones and royalties following the relaunch providing a significant future source of non-dilutive capital.”
About SCYNEXIS
SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. SCYNEXIS is developing the company’s proprietary antifungal platform “fungerps.” Ibrexafungerp, the first representative of this novel class, has been licensed to GSK. The U.S. Food and Drug Administration (FDA) has approved BREXAFEMME® (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC) and for reduction in the incidence of recurrent VVC. Additional antifungal assets from this novel class are currently in clinical, pre-clinical and discovery phases, including the compound SCY-247. For more information, visit
www.scynexis.com
.
Forward-Looking Statements
Statements contained in this press release regarding expected future events or results are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements regarding: receipt of milestones and royalties from GSK. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks inherent in regulatory and other costs in developing products. These and other risks are described more fully in SCYNEXIS' filings with the Securities and Exchange Commission, including without limitation, its most recent Annual Report on Form 10-K filed on March 12, 2025, including under the caption "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made. SCYNEXIS undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
CONTACT
:
Investor Relations
Irina Koffler
LifeSci Advisors
Tel: 917-734-7387
[email protected]
